Europe – NICE no for BMS’ multiple sclerosis drug Zeposia

The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s (BMS) Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS).

In an appraisal consultation document, NICE said that although there is evidence that Zeposia can reduce the number relapses and brain lesions compared to interferon beta-1a, the drug’s effect on disability progression is unclear.

NICE also said that the cost-effectiveness estimates for Zeposia were uncertain due to the ‘limitations’ In the clinical effectiveness evidence, adding that they ‘are above what NICE normally considers an acceptable use of NHS resources’.

Last May, Zeposia was cleared by the European Medicines Agency for the treatment of RRMS and also gained an approval from the US Food and Drug Administration (FDA) last year…